• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Organisation › Details

AstraZeneca (Group)

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
In the United States, AstraZeneca is a $12.44 billion healthcare business with more than 12,000 employees. For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over $3 billion in savings to more than 1 million patients throughout the US and Puerto Rico. *

 

	Start	1999-04-05 merged
	Predecessor	Zeneca (Group)
	Industry	pharmaceutical
	Person	Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)
	Person 2	Dunoyer, Marc (AstraZeneca 201311– CFO joined 201303 as EVP Global Portfolio + Product Strategy before GSK)
	Region	United Kingdom (town unspecified)
	Country	United Kingdom (GB)
	Street	15 Stanhope Gate
	City	W1K 1LN London
	Tel	+44-20-7304-5000
		Address record changed: 2018-07-24
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	22,465,000,000 (revenue, total, consolidated (2017) 2017-12-31)
	Profit	2,868,000,000 (2017-12-31)
	Cash	3,324,000,000 (2017-12-31)
		* Document for �About Section�:
		Record changed: 2019-06-09

Advertisement

More documents for AstraZeneca (Group)

• [1] Cell Mogrify Ltd.. (9/9/19). "Press Release: Mogrify Appoints Dr. Jane Osbourn, OBE as Chair". Cambridge....
• [2] Theragnostics Ltd.. (9/5/19). "Press Release: Theragnostics Signs Agreement with AstraZeneca". London....
• [3] AstraZeneca plc. (8/22/19). "Press Release: AstraZeneca Agrees to Buy US FDA Priority Review Voucher from Sobi"....
• [4] AstraZeneca plc. (8/22/19). "Press Release: Roxadustat Approved in China for the Treatment of Anaemia in Non-dialysis-dependent Patients with Chronic Kidney Disease"....
• [5] AstraZeneca plc. (8/21/19). "Press Release: Update on the Phase III NEPTUNE Trial of Imfinzi plus Tremelimumab in Stage IV Non-small Cell Lung Cancer"....
• [6] AstraZeneca plc. (8/20/19). "Press Release: Farxiga Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients with Heart Failure"....
• [7] Pieris Pharmaceuticals, Inc.. (8/1/19). "Press Release: Pieris Pharmaceuticals Reports Second Quarter 2019 Cash Position and Provides Corporate Update". Boston, MA....
• [8] Genedata AG. (6/25/19). "Press Release: Genedata Expands Collaboration with AstraZeneca on Deep Learning for High-Content Image Analysis". Basel....
• [9] Arcus Biosciences, Inc.. (6/24/19). "Press Release: Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer". Hayward, CA....
• [10] Immunocore Ltd.. (5/7/19). "Press Release: Immunocore Appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer". Oxfordshire, Pennsylvania & Maryland....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.